

2026 Industry Workshop Schedule

All industry workshops take place in the Walter E. Washington Convention Center.

ACOG recognizes that Industry Workshops are promotional in nature and may focus on a specific product or drug. These sessions are not approved for continuing education credits.

FRIDAY, MAY 1

(IW-1)

Breakfast | 7–7:45 a.m. | Room 206

Screen + Detect Cancer Early: How the Cologuard Plus® and Cancersguard® Tests Can Help You Expand Early Detection with Confidence

Join us for a focused discussion on the evolving landscape of early cancer detection and the growing role of innovative screening tools. We'll explore how the Cologuard Plus® test and the Cancersguard® multicancer early detection test work together to help clinicians identify more cancers at earlier, more treatable stages. Attendees will gain practical insights into test performance, clinical integration, and strategies to strengthen early detection—especially as cancer rates rise in younger adults and most cancers lack routine screening.

Supported by: Exact Sciences

Speakers: Robyn Roth, MD, and Cedrina Calder, MD, MSPH

(IW-2)

Breakfast | 7–7:45 a.m. | Room 207A

PrEP for Her: HIV Prevention in Cisgender Women

Preexposure prophylaxis (PrEP) is a highly effective intervention for preventing HIV acquisition. Despite its proven effectiveness, PrEP uptake in the United States has been disproportionately low among certain populations, particularly in cisgender women. This session will dive into the epidemiology of the HIV landscape specifically to cisgender women in the United States, exploring differences across race and geography; it will also highlight key factors that impact HIV prevention and PrEP use among this population, including barriers to uptake, clinical considerations, and strategies to improve engagement through FDA-approved PrEP options available for women.

Supported by: Gilead Sciences

Speakers: Toyin Nwafor, MD, and Gina Brown, MD

(IW-3)

Breakfast | 7–7:45 a.m. | Room 207B

Common, Normalized, Untreated: The Pelvic Health Gap in Women's Care

Vaginal and lower urinary tract symptoms are highly prevalent across the lifespan but remain under-recognized in routine gynecologic care. Barriers include limited screening, normalization of symptoms, and underutilization of available therapies. This session will review common presentations, clarify overlapping conditions such as

genitourinary syndrome of menopause, and provide evidence-based approaches to management. Emphasis will be placed on practical, time-efficient strategies and a range of treatment options (eg, prescription, over-the-counter, botanical) to support individualized, patient-centered care.

Supported by: AZO® Urinary & Vaginal Health Products

Speaker: Alexandra Dubinskaya, MD, NCMP

(IW-4)

Lunch | Noon–12:45 p.m. | Room 206

Learn about a Nonhormonal FDA-Approved Treatment for Moderate to Severe Vasomotor Symptoms Due to Menopause

In this session, we will review an FDA-approved treatment for moderate to severe vasomotor symptoms due to menopause, including indication, mechanism of action, and clinical safety and efficacy.

Supported by: Astellas Pharma US, Inc.

Speakers: Lisa Chism, DNP, APRN, BC, CSC, MSCP, FAAN, FAANP, and Alyse Kelly-Jones, MD, FACOG, IF

(IW-5)

Lunch | Noon–12:45 p.m. | Room 207A

Screen Smarter, Not Harder: Extended Genotyping, HPV Primary Testing, and HPV Self-Collection Implementation

Join Dr. Leeya Pinder, MD, MPH, for a modernized, patient-centered look at making cervical screening work for real patients. This symposium spotlights the BD Onclarity™ HPV Assay, which leverages extended genotyping to inform risk stratification and follow-up, enabling a variety of HPV primary testing pathways, including HPV self-collection. With a strong emphasis on self-collection as an option to “meet patients where they are,” Dr. Pinder will share real-world lessons from implementing new screening approaches in her health system. Attendees will leave with practical considerations to expand access, drive increased screening, and move closer toward cervical cancer elimination in our lifetime.

Supported by: BD Onclarity™ HPV Assay

Speaker: Leeya F. Pinder, MD, MPH

(IW-6)

Lunch | Noon–12:45 p.m. | Room 207B

Advancing beyond Gut Sutures: Join a peer-to-peer lunch for practical insights and best practices to optimize outcomes

Optimize outcomes in obstetrics and gynecology through advanced wound closure products.

Supported by: Johnson & Johnson MedTech

Speakers: Jonathan Black, MD, MPH, and Youssef Mouhayar, MD

(IW-7)

**Lunch | Noon–12:45 p.m. | Exhibit Hall Theater 1
Applying the Continuum of Care to Strengthen STI Management**

Sexually transmitted infections (STIs) continue to affect millions of people in the United States. Join us for this interactive roundtable discussion that will explore the full continuum of care for STIs—from screening, symptoms, treatment, vaginitis coinfection management, and retesting—using current data and guideline-based strategies. Recent STI incidence trends will be reviewed, as well as how these trends inform risk assessment and screening priorities across clinical settings. This panel discussion will cover best practices for implementing screening guidelines and demonstrate how to integrate these approaches into everyday workflows. The frequency of STI coinfections will be discussed with diagnostic and treatment strategies.

Supported by: Hologic

Speakers: Kyle Bukowski, MD, FACOG; Shruti Bala, MD MPH, FACOG; and Ada Stewart, MD, FAAFP

(IW-8)

**Lunch | Noon–12:45 p.m. | Exhibit Hall Theater 2
A Respiratory Syncytial Virus (RSV) Prevention Option**

Join us for a Pfizer-sponsored informational session in which we will ...

- Highlight the burden of disease in infants, including risk of RSV-associated hospitalizations
- Discuss the clinical trial data and real-world evidence for an RSV prevention option
- Learn about the CDC recommendation for an RSV vaccine prevention option

Supported by: Pfizer Inc.

Speaker: Ashanda Saint Jean, MD, FACOG

(IW-9)

**Afternoon Break | 2:35–3:05 p.m. | Exhibit Hall Theater 1
Reimagining Menopause Care: Nonhormonal Solutions That Open the Door to HRT**

As demand for individualized menopause care grows, clinicians need flexible, evidence-based tools that meet patients where they are. This session examines the role of nonhormonal therapies—particularly rhapontic rhubarb extract—as impactful options for symptom relief when HRT is delayed, inaccessible, or contraindicated. We will explore how these therapies can reduce barriers, support patient readiness for HRT, and offer meaningful alternatives to prescription nonhormonal agents. Attendees will gain actionable insights to expand treatment pathways and deliver more inclusive, responsive menopause care.

Supported by: Estroven® Complete Menopause Relief

Speaker: Kerry-Anne Perkins, DO, MBA, MS, FACOG

(IW-10)

**Afternoon Break | 2:35–3:05p.m. | Exhibit Hall Theater 2
From Wet Mount to NAAT Point of Care: Getting Vaginitis Diagnosis and Treatment RIGHT**

Dr. Sharon Hillier will present results from a randomized controlled trial conducted in ob-gyn clinic settings comparing usual diagnostic care with a rapid, point-of-care nucleic acid amplification test (NAAT), the Xpert Xpress MVP. The study evaluates diagnostic accuracy and treatment appropriateness across both arms. Findings highlight the limitations of traditional methods such as wet mount microscopy and Amsel Criteria and demonstrate how molecular point-of-care testing can improve detection of BV, VVC, and TV, enabling more precise, same-visit treatment decisions and advancing standards for vaginitis care.

Supported by: Cepheid

Speaker: Sharon L. Hillier, PhD

(IW-11)

**Reception | 5:30–6:15 p.m. | Room 206
From Discovery to Impact: GnRH Targeted Therapies for Symptom Management in Endometriosis and Uterine Fibroids**

The evolution of GnRH targeted therapies has transformed the management of endometriosis and uterine fibroids. Join Dr. Taraneh Shirazian and Dr. Kirsten Sasaki as they discuss the development and mechanism of GnRH antagonists and examine how these therapies translate into clinically meaningful symptom management for patients with pain in endometriosis and heavy menstrual bleeding in uterine fibroids.

Supported by: Sumitomo Pharma America Medical Affairs

Speakers: Taraneh Shirazian, MD, FACOG, and Kirsten J. Sasaki, MD, FACOG

SATURDAY, MAY 2

(IW-12)

**Breakfast | 7–7:45 a.m. | Room 206
Explore LYNKUET® (elinzanetant) 60mg Capsules: An FDA-Approved Treatment Option for Your Appropriate Patients**

This session will provide an overview of LYNKUET's efficacy and safety profile, its mechanism of action, and how to access LYNKUET.

Website - <https://www.LynkuetHCP.com>

Supported by: Bayer

Speaker: James A. Simon, MD, FACOG

(IW-13)**Breakfast | 7–7:45 a.m. | Room 207A****Brighter Tomorrows: Advancing Evidence-Based Innovations in Maternal and Neonatal Health**

Join us for a discussion about the PreTRM[®] Test, a blood-based biomarker test for identification of patients at higher risk for spontaneous preterm birth, and multidisciplinary interventions that improve maternal and neonatal health outcomes.

Supported by: Sera Prognostics

Speaker: Tiffany Inglis, MD, and Scott Sullivan, MD, FACOG

(IW-14)**Breakfast | 7–7:45 a.m. | Room 207B****A Treatment Option for Your Adult Patients with Postpartum Depression**

Supernus Pharmaceuticals is a biopharmaceutical company focused on the development of therapies for neurological and psychiatric conditions, including central nervous system disorders. Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients' lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment, to deliver long-term growth.

Supported by: Supernus Pharmaceuticals, Inc. and Biogen Inc.

Speaker: Jason James, MD, FACOG

(IW-15)**Lunch | Noon–12:45 p.m. | Room 206****Optimizing Prenatal Nutrition and Supplementation: Evidence-Informed Strategies in Clinical Practice**

Proper nutrition is foundational for a healthy pregnancy, but many patients fall short of key nutrients. This session will highlight nutrient gaps and explain the role of nutrients in prenatal supplementation. Notably, the session will include evidence for vitamins and minerals, along with information on choline, DHA, lutein and zeaxanthin, and how they help ensure the best outcomes for moms and babies throughout pregnancy and postpartum. Clinicians will be equipped with evidence-informed insights that can be applied in everyday practice. This will include a deeper understanding of key nutrients, their synergistic interactions, and how to address nutritionally relevant questions.

Supported by: Council for Responsible Nutrition Foundation, Prenatal Nutrition Center

Speakers: Danielle Christifano, PhD, and Leslie Stone, MD, ABFM, FM/OB Fellow, IFM-CP

(IW-16)**Lunch | Noon–12:45 p.m. | Room 207A****How Alaska is Revolutionizing Cervical Cancer Detection with HPV Primary Screening and Dual-Stain Triage**

This session examines cervical cancer disparities within Alaska Native communities and the role of primary HPV screening and dual-stain triage in closing gaps in early detection. Participants will explore implementation science frameworks used by tribal health organizations to integrate evidence-based strategies into complex system workflows, including clinics, labs, and EHR systems. The presentation highlights the successes and challenges of deploying cervical cancer screening and detection models (ie, primary HPV screening, self-collection, and dual-stain cytology) across Alaska's diverse urban and rural landscapes. Attendees will gain practical insights into navigating systemic changes to improve oncological outcomes in indigenous health systems.

Supported by: Roche Diagnostics Corporation

Speakers: Bethany R. Berry, CNM, MSN, and James J. Tiesinga, MD

(IW-17)**Lunch | Noon–12:45 p.m. | Room 207B****Combating Congenital Syphilis: Drive Better Outcomes for Mothers and Babies**

Congenital syphilis rates continue to rise, posing serious risks to maternal and neonatal health. In response to this growing public health crisis, health authorities have updated screening guidelines for pregnancy. This industry workshop will explore current disease trends, evolving clinical guidance, and evidence-based testing recommendations to support timely identification and management of syphilis during pregnancy. Led by Dr. Liza Kunz of Abbott Core Diagnostics, a medical leader in women's health and Fellow of ACOG, this session will highlight practical screening and testing considerations to help drive earlier detection and better outcomes for mothers and babies.

Supported by: Abbott Laboratories

Speaker: Liza Kunz, MD, FACOG

(IW-18)**Lunch | Noon–12:45 p.m. | Exhibit Hall Theater 1****Natural Cycles: Reshaping the Birth Control Landscape with the First and Only FDA-Cleared Digital Contraceptive**

Discover Natural Cycles, the first and only FDA-cleared digital contraceptive. This nonhormonal method is 93% effective with typical use, reshaping the contraception landscape. Explore the scientific foundation, proven effectiveness, and real-world results behind Natural Cycles birth control. This session will clarify how regulated digital contraception differs from non-regulated period tracking apps and discuss its place among other FDA-cleared methods. Industry experts will address common questions

and misconceptions, discussing why Natural Cycles may be an excellent nonhormonal, side-effect-free option for your patients. Attendees will gain practical guidance for patient counseling, prescribing, and integrating Natural Cycles into routine clinical practice.

Supported by: Natural Cycles

Speakers: Karen Tang, MD, MPH, and Eleonora Benhar Nocchioli, PhD

(IW-19)

Lunch | Noon–12:45 p.m. | Exhibit Hall Theater 2
Learn About a PrEP Injectable Option

Explore the evidence of PrEP as a highly effective but underutilized HIV prevention strategy, including opportunities to further decrease HIV diagnoses, especially in underserved populations. Select details on clinical trial data for an injectable PrEP option and information about its use in clinical practice will also be examined.

Supported by: Gilead Sciences, Inc.

Speaker: TBA

(IW-20)

Reception | 5:30–6:15 p.m. | Room 206
Closing the Gap in Cesarean Outcomes: Real-World Insights That Change Practice

Join us for an evidence-driven reception exploring new Premier real-world data on cesarean delivery outcomes and the impact of incision management on maternal recovery. This program will highlight key trends in complications, best-practice opportunities, and practical approaches to optimize care pathways along with identification of socioeconomic and clinical risk factors that contribute to disparate maternal outcomes. Attendees will gain actionable insights to support stronger decision making, greater standardization, and improved outcomes in postoperative cesarean management—supported by peer-to-peer discussion and clinical experience sharing.

Supported by: Smith&Nephew, Inc.

Speaker: Sebastian Hobson, MD, PhD, MPH, FRANZCOG, FACOG, FRCSC

SUNDAY, MAY 3

(IW-21)

Breakfast | 7–7:45 a.m. | Room 206

FirstGene® Multiple Prenatal Screen: Advancing Prenatal Screening Through Integrated Technology

How do emerging prenatal screening technologies perform in real clinical scenarios? This session introduces FirstGene® Multiple Prenatal Screen, a single-draw prenatal screen designed to assess multiple genetic risks at once, followed by case examples. Attendees will gain insight into the test design, including the next advancements to our proprietary AMPLIFY® technology. You'll learn how these integrated results may help address common challenges such as unavailable partner testing and complex carrier scenarios.

Supported by: Myriad Genetics

Speakers: Dale Muzzey, PhD, and Dallas Reed, MD, FACMG, FACOG